37136-92-8

Usage

Uses

Used in Pharmaceutical Industry:
2-(2-BROMOETHOXY)-1,3-DIMETHYLBENZENE is used as an intermediate in the synthesis of pharmaceuticals for its ability to facilitate the production of specific medicinal compounds.
Used in Agrochemical Industry:
In the agrochemical sector, 2-(2-BROMOETHOXY)-1,3-DIMETHYLBENZENE serves as an intermediate, playing a crucial role in the creation of various agrochemicals that aid in crop protection and enhancement.
Used in Specialty Chemicals Production:
2-(2-BROMOETHOXY)-1,3-DIMETHYLBENZENE is utilized as a solvent and an intermediate in the production of specialty chemicals, contributing to the development of unique chemical formulations for specific applications.
Safety Measures:
It is important to handle 2-(2-BROMOETHOXY)-1,3-DIMETHYLBENZENE with care due to its potential hazardous properties, such as flammability and its ability to cause skin and eye irritation upon contact. Proper safety measures should be employed during its use to mitigate these risks.

InChI:InChI=1/C10H13BrO/c1-8-4-3-5-9(2)10(8)12-7-6-11/h3-5H,6-7H2,1-2H3

Upstream product

• 576-26-1 2.6-dimethylphenol 
• 106-93-4 ethylene dibromide 
• 557-91-5 1,1-Dibromoethane 
• 16737-71-6 2-(2,6-dimethylphenoxy)ethanol 
• 16081-16-6 sodium 2,6-dimethylphenolate 

Downstream Products

• 6320-62-3 2-(2-Diethylamino-ethoxy)-1,3-dimethyl-benzol 
• 7633-89-8 triethyl-[2-(2,6-dimethyl-phenoxy)-ethyl]-ammonium; bromide 
• 93994-27-5 [4-(2-Bromo-ethoxy)-3,5-dimethyl-phenyl]-m-tolyl-methanone 
• 73446-32-9 1-[2-(2,6-dimethyl-phenoxy)-ethyl]piperazine 
• 313375-57-4 2-((2-(2,6-dimethylphenoxy)ethyl)thio)-1H-benzo[d]imidazole 
• 1429289-62-2 C₂₇H₃₀N₂O₂S 
• 1352874-95-3 N-(thiazol-2-yl)-2-(4-(2-(2,6-dimethylphenoxy)ethyl)piperazin-1-yl)acetamide 
• 1347727-76-7 trans-(±)-4N-[(2,6-dimethylphenoxy)ethyl]aminocyclohexan-1-ol 

Relevant academic research and scientific papers

Synthesis, antimicrobial evaluation, and in silico studies of quinoline—1H-1,2,3-triazole molecular hybrids

Abstract: Antimicrobial resistance has become a significant threat to global public health, thus precipitating an exigent need for new drugs with improved therapeutic efficacy. In this regard, molecular hybridization is deemed as a viable strategy to afford multi-target-based drug candidates. Herein, we report a library of quinoline—1H-1,2,3-triazole molecular hybrids synthesized via copper(I)-catalyzed azide-alkyne [3 + 2] dipolar cycloaddition reaction (CuAAC). Antimicrobial evaluation identified compound 16 as the most active hybrid in the library with a broad-spectrum antibacterial activity at an MIC80 value of 75.39?μM against methicillin-resistant S. aureus, E. coli, A. baumannii, and multidrug-resistant K. pneumoniae. The compound also showed interesting antifungal profile against C. albicans and C. neoformans at an MIC80 value of 37.69 and 2.36?μM, respectively, superior to fluconazole. In vitro toxicity profiling revealed non-hemolytic activity against human red blood cells (hRBC) but partial cytotoxicity to human embryonic kidney cells (HEK293). Additionally, in silico studies predicted excellent drug-like properties and the importance of triazole ring in stabilizing the complexation with target proteins. Overall, these results present compound 16 as a promising scaffold on which other molecules can be modeled to deliver new antimicrobial agents with improved potency. Graphic abstract: [Figure not available: see fulltext.].

Synthesis and Investigation of S-Substituted 2-Mercaptobenzoimidazoles as Inhibitors of Hedgehog Signaling

Due to the arising resistance of common drugs targeting the Hedgehog signaling pathway, the identification of new compound classes with inhibitory effect is urgently needed. We were able to identify S-alkylated 2-mercaptobenzoimidazoles as a new compound

Zirconium complexes with pendant aryloxy groups attached to the metallocene moiety by ethyl or hexyl spacers

Four zirconium complexes with pendant aryloxy groups attached to the metallocene moiety by ethyl or hexyl spacers have been synthesized and characterized by spectroscopic methods and HR-MS or elemental analysis. The solid state structure of bis[{6-(2,6-dimethylphenoxy)hexyl}cyclopentadienyl] zirconium dichloride was determined by single crystal X-ray diffraction. The prepared complexes were tested as catalyst precursors in the polymerization of ethylene upon activation with MAO. The results showed a marked effect of the spacer length on the catalytic activity, while only a minor effect of the substitution on the aryl group, which affected its steric properties.

Discovery of 1-aryloxyethyl piperazine derivatives as Kv1.5 potassium channel inhibitors (part I)

Kv1.5 potassium channel is an efficacious and safe therapeutic target for the treatment of atrial fibrillation (AF), the most common arrhythmia that threatens human. Herein, by modifying the hit compound 7k from an in-house database, 48 derivatives were synthesized for the assay of their Kv1.5 inhibitory effects by whole cell patch clamp technique. Six compounds which showed better potency than the positive compound dronedarone were selected for the next evaluation of their drug-like properties. Compound 8 exhibited balanced solubility and permeability. It also showed acceptable pharmacodynamics profile with very low acute toxicity. Taking all these data into account, compound 8 can serve as a promising lead for the development of novel therapeutic agent for the treatment of AF.

BENZIMIDAZOLE DERIVATIVES AS SELECTIVE BLOCKERS OF PERSISTENT SODIUM CURRENT

The present invention is directed to methods of treating diseases or conditions mediated by elevated persistent sodium channel, such as ocular disorders, pain, multiple sclerosis, and seizure disorders utilizing a compound of Formula I or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising said compound, wherein variables R, R1, R2, R3, R4, R5, m, and n in Formula I are as defined herein

Renin inhibitors

The invention relates to compounds having the formula: wherein the variables are as defined herein. The invention further relates to methods of making and using these compounds, and pharmaceutical compositions, kits and articles of manufacture comprise th

Synthesis and anticonvulsant activity of trans- and cis-2-(2,6- dimethylphenoxy)-N-(2- or 4-hydroxycyclohexyl)acetamides and their amine analogs

A group of trans- and cis-2-(2,6-dimethylphenoxy)-N-(2-hydroxycyclohexyl) acetamides (1-7) and -ethylamines (8-9) have been synthesized and investigated for their anticonvulsant activity. One of them, racemic trans-2-(2,6- dimethylphenoxy)-N-(2-hydroxycyclohexyl)acetamide proved to be the most effective in MES (mice, ip), exhibiting ED50 = 42.97 mg/kg b.w. and TD50 = 105.67 mg/kg b.w. It also proved protection in focal seizures (electric kindling, rats, ip) and it raises seizure threshold. The mechanism of action is inhibition of voltage-gated sodium currents and enhancement of GABA effect. Safety pharmacology assay on threshold tonic extension revealed no lowering of the seizure threshold.

Synthesis and anticonvulsant activity of 1,2-aminoalkanol derivatives

A series of 1,2-aminoalkanol derivatives were prepared and evaluated for anticonvulsant activity in the maximal electroshock seizure (MES) and subcutaneous pentylenetetrazole seizure threshold (scMet) assays and for neurotoxicity (TOX). Most interesting were the anticonvulsant results of S-(+)-2-amino-1-butanol derivative VIII, which displayed anti-MES activity with a protective index (TD50/ED50) of 4.55 corresponding with that for phenytoin, carbamazepine and valproate.

Piperazines and therapeutic utility

The invention relates to compounds having the formula: STR1 in which: the substituents R1, R2 and R3 represent independently from each other a hydrogen atom, a halogen atom, a trifluoromethyl radical, a saturated or unsatu